Inventiva announces that, following consultation with the US FDA, it has decided to revise the clinical development plan for lanifibranor for the treatment of NASH (non-alcoholic steatohepatitis).

These changes, which should benefit the clinical program, include the preparation of a new Phase III study in NASH patients with compensated cirrhosis.

If successful, the results of this Phase III study should make it possible to submit the final marketing authorization application to the FDA and expand the target patient population beyond patients with F2 and F3 fibrosis.

Copyright (c) 2023 CercleFinance.com. All rights reserved.